CSNpharm

CSNpharm logo

Csnpharm is committed to providing you with high quality products and outstanding services. We supply over 5000 bioactive compounds in stock, including inhibitors, agonists and natural products for laboratory and scientific use. Csnpharm has always been committed to develop quality products that are validated by NMR, UPLC, LC-MS, GC, Chiral HPLC and so on. We have a professional technical support team for customer service with years of experience in life science. Csnpharm is your reliable partner for scientific research.

Company Website

Product Listing

BC-1215 5mg  | ≥99%

CSNpharm

BC-1215 is a FBXO3 inhibitor which can decrease FBXO3-Fbxl2 interaction. BC-1215 inhibited the FBXO3-TRAF activation pathway by destabilizing TRAF1–TRAF6.

More Information Supplier Page

BC-1215 10mg  | ≥99%

CSNpharm

BC-1215 is a FBXO3 inhibitor which can decrease FBXO3-Fbxl2 interaction. BC-1215 inhibited the FBXO3-TRAF activation pathway by destabilizing TRAF1–TRAF6.

More Information Supplier Page

BC-1215 25mg  | ≥99%

CSNpharm

BC-1215 is a FBXO3 inhibitor which can decrease FBXO3-Fbxl2 interaction. BC-1215 inhibited the FBXO3-TRAF activation pathway by destabilizing TRAF1–TRAF6.

More Information Supplier Page

BC-1215 50mg  | ≥99%

CSNpharm

BC-1215 is a FBXO3 inhibitor which can decrease FBXO3-Fbxl2 interaction. BC-1215 inhibited the FBXO3-TRAF activation pathway by destabilizing TRAF1–TRAF6.

More Information Supplier Page

BCTC 25mg  | ≥99%

CSNpharm

BCTC is a potent and specific inhibitor of transient receptor potential cation channel subfamily M member 8 (TRPM8) in prostate cancer (PCa) DU145 cells.

More Information Supplier Page

BCTC 10mg  | ≥99%

CSNpharm

BCTC is a potent and specific inhibitor of transient receptor potential cation channel subfamily M member 8 (TRPM8) in prostate cancer (PCa) DU145 cells.

More Information Supplier Page

BCTC 50mg  | ≥99%

CSNpharm

BCTC is a potent and specific inhibitor of transient receptor potential cation channel subfamily M member 8 (TRPM8) in prostate cancer (PCa) DU145 cells.

More Information Supplier Page

BCTC 5mg  | ≥99%

CSNpharm

BCTC is a potent and specific inhibitor of transient receptor potential cation channel subfamily M member 8 (TRPM8) in prostate cancer (PCa) DU145 cells.

More Information Supplier Page

BD-1047 Dihydrobromide 50mg  | ≥99%

CSNpharm

BD-1047 dihydrobromide is a selective functional antagonist of sigma receptors, shows antipsychotic activity in animal models predictive of efficacy in schizophrenia.

More Information Supplier Page

BD-1047 Dihydrobromide 1mg  | ≥99%

CSNpharm

BD-1047 dihydrobromide is a selective functional antagonist of sigma receptors, shows antipsychotic activity in animal models predictive of efficacy in schizophrenia.

More Information Supplier Page

BD-1047 Dihydrobromide 5mg  | ≥99%

CSNpharm

BD-1047 dihydrobromide is a selective functional antagonist of sigma receptors, shows antipsychotic activity in animal models predictive of efficacy in schizophrenia.

More Information Supplier Page

BD-1047 Dihydrobromide 10mg  | ≥99%

CSNpharm

BD-1047 dihydrobromide is a selective functional antagonist of sigma receptors, shows antipsychotic activity in animal models predictive of efficacy in schizophrenia.

More Information Supplier Page

BDA-366 10mg  | ≥98%

CSNpharm

BDA-366 is a small-molecule Bcl2-BH4 domain antagonist and binds BH4 with high affinity and selectivity.

More Information Supplier Page

BDA-366 5mg  | ≥98%

CSNpharm

BDA-366 is a small-molecule Bcl2-BH4 domain antagonist and binds BH4 with high affinity and selectivity.

More Information Supplier Page

BDA-366 25mg  | ≥98%

CSNpharm

BDA-366 is a small-molecule Bcl2-BH4 domain antagonist and binds BH4 with high affinity and selectivity.

More Information Supplier Page

BDA-366 1mg  | ≥98%

CSNpharm

BDA-366 is a small-molecule Bcl2-BH4 domain antagonist and binds BH4 with high affinity and selectivity.

More Information Supplier Page

BEC HCl 25mg  | ≥99%

CSNpharm

BEC HCl is a competitive arginase inhibitor with Ki of 0.31 μM and 0.4-0.6 μM for Arginase II and rat Arginase I respectively.

More Information Supplier Page

BEC HCl 10mg  | ≥99%

CSNpharm

BEC HCl is a competitive arginase inhibitor with Ki of 0.31 μM and 0.4-0.6 μM for Arginase II and rat Arginase I respectively.

More Information Supplier Page

BEC HCl 1mg  | ≥99%

CSNpharm

BEC HCl is a competitive arginase inhibitor with Ki of 0.31 μM and 0.4-0.6 μM for Arginase II and rat Arginase I respectively.

More Information Supplier Page

BEC HCl 5mg  | ≥99%

CSNpharm

BEC HCl is a competitive arginase inhibitor with Ki of 0.31 μM and 0.4-0.6 μM for Arginase II and rat Arginase I respectively.

More Information Supplier Page

BEC HCl 50mg  | ≥99%

CSNpharm

BEC HCl is a competitive arginase inhibitor with Ki of 0.31 μM and 0.4-0.6 μM for Arginase II and rat Arginase I respectively.

More Information Supplier Page

Beclamide 100mg  | ≥98%

CSNpharm

Beclamide is a drug that possesses anticonvulsant activity, has been used as a sedative and as an anticonvulsant.

More Information Supplier Page

Beclamide 25mg  | ≥98%

CSNpharm

Beclamide is a drug that possesses anticonvulsant activity, has been used as a sedative and as an anticonvulsant.

More Information Supplier Page

Bedaquiline Fumarate 5mg  | ≥98%

CSNpharm

Bedaquiline fumarate, a diarylquinoline antibiotic that targets ATP synthase, is effective for the treatment of Mycobacterium tuberculosis infections.

More Information Supplier Page

Bedaquiline Fumarate 1mg  | ≥98%

CSNpharm

Bedaquiline fumarate, a diarylquinoline antibiotic that targets ATP synthase, is effective for the treatment of Mycobacterium tuberculosis infections.

More Information Supplier Page